These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 19204207)

  • 41. Clinical significance of molecular biomarkers in glioblastoma.
    Ang C; Guiot MC; Ramanakumar AV; Roberge D; Kavan P
    Can J Neurol Sci; 2010 Sep; 37(5):625-30. PubMed ID: 21059509
    [TBL] [Abstract][Full Text] [Related]  

  • 42. EGFR amplification and EGFRvIII predict and participate in TAT-Cx43266-283 antitumor response in preclinical glioblastoma models.
    Álvarez-Vázquez A; San-Segundo L; Cerveró-García P; Flores-Hernández R; Ollauri-Ibáñez C; Segura-Collar B; Hubert CG; Morrison G; Pollard SM; Lathia JD; Sánchez-Gómez P; Tabernero A
    Neuro Oncol; 2024 Jul; 26(7):1230-1246. PubMed ID: 38507464
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results.
    Salmaggi A; Milanesi I; Silvani A; Gaviani P; Marchetti M; Fariselli L; Solero CL; Maccagnano C; Casali C; Guzzetti S; Pollo B; Ciusani E; Dimeco F
    J Neurosurg; 2013 Apr; 118(4):821-9. PubMed ID: 23350777
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
    Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y;
    Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme.
    Barrié M; Couprie C; Dufour H; Figarella-Branger D; Muracciole X; Hoang-Xuan K; Braguer D; Martin PM; Peragut JC; Grisoli F; Chinot O
    Ann Oncol; 2005 Jul; 16(7):1177-84. PubMed ID: 15857844
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel.
    Sarkaria JN; Yang L; Grogan PT; Kitange GJ; Carlson BL; Schroeder MA; Galanis E; Giannini C; Wu W; Dinca EB; James CD
    Mol Cancer Ther; 2007 Mar; 6(3):1167-74. PubMed ID: 17363510
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma.
    DI Cristofori A; Carrabba G; Lanfranchi G; Menghetti C; Rampini P; Caroli M
    Anticancer Res; 2013 Aug; 33(8):3383-9. PubMed ID: 23898108
    [TBL] [Abstract][Full Text] [Related]  

  • 48. NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma.
    Gilbert MR; Pugh SL; Aldape K; Sorensen AG; Mikkelsen T; Penas-Prado M; Bokstein F; Kwok Y; Lee RJ; Mehta M
    J Neurooncol; 2017 Jan; 131(1):193-199. PubMed ID: 27770279
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas.
    Raizer JJ; Abrey LE; Lassman AB; Chang SM; Lamborn KR; Kuhn JG; Yung WK; Gilbert MR; Aldape KD; Wen PY; Fine HA; Mehta M; Deangelis LM; Lieberman F; Cloughesy TF; Robins HI; Dancey J; Prados MD;
    Neuro Oncol; 2010 Jan; 12(1):87-94. PubMed ID: 20150371
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?
    Boiardi A; Silvani A; Eoli M; Lamperti E; Salmaggi A; Gaviani P; Fiumani A; Botturi A; Falcone C; Solari A; Filippini G; Di Meco F; Broggi G
    J Neurooncol; 2008 May; 88(1):105-13. PubMed ID: 18283418
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study.
    Yu A; Faiq N; Green S; Lai A; Green R; Hu J; Cloughesy TF; Mellinghoff I; Nghiemphu PL
    J Neurooncol; 2017 Sep; 134(2):357-362. PubMed ID: 28669012
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer.
    Li T; Piperdi B; Walsh WV; Kim M; Beckett LA; Gucalp R; Haigentz M; Bathini VG; Wen H; Zhou K; Pasquinelli PB; Gajavelli S; Sreedhara M; Xie X; Lara PN; Gandara DR; Perez-Soler R
    Clin Lung Cancer; 2017 Jan; 18(1):60-67. PubMed ID: 27919627
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the Brain Tumor Investigational Consortium (BTIC).
    Chamberlain MC; Grimm S; Phuphanich S; Recht L; Zhu JZ; Kim L; Rosenfeld S; Fadul CE;
    J Neurooncol; 2014 Jun; 118(2):335-343. PubMed ID: 24740196
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
    Urata Y; Katakami N; Morita S; Kaji R; Yoshioka H; Seto T; Satouchi M; Iwamoto Y; Kanehara M; Fujimoto D; Ikeda N; Murakami H; Daga H; Oguri T; Goto I; Imamura F; Sugawara S; Saka H; Nogami N; Negoro S; Nakagawa K; Nakanishi Y
    J Clin Oncol; 2016 Sep; 34(27):3248-57. PubMed ID: 27022112
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.
    Cho J; Pastorino S; Zeng Q; Xu X; Johnson W; Vandenberg S; Verhaak R; Cherniack AD; Watanabe H; Dutt A; Kwon J; Chao YS; Onofrio RC; Chiang D; Yuza Y; Kesari S; Meyerson M
    Cancer Res; 2011 Dec; 71(24):7587-96. PubMed ID: 22001862
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase I/II study of oral erlotinib for treatment of relapsed/refractory glioblastoma multiforme and anaplastic astrocytoma.
    Kesavabhotla K; Schlaff CD; Shin B; Mubita L; Kaplan R; Tsiouris AJ; Pannullo SC; Christos P; Lavi E; Scheff R; Boockvar JA
    J Exp Ther Oncol; 2012; 10(1):71-81. PubMed ID: 22946346
    [TBL] [Abstract][Full Text] [Related]  

  • 58. How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial.
    Brandes AA; Tosoni A; Amistà P; Nicolardi L; Grosso D; Berti F; Ermani M
    Neurology; 2004 Oct; 63(7):1281-4. PubMed ID: 15477552
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tailored therapy for recurrent glioblastoma: report of a personalized molecular approach.
    D'Alessandris QG; Martini M; Cenci T; DI Bonaventura R; Lauretti L; Stumpo V; Olivi A; Larocca LM; Pallini R; Montano N
    J Neurosurg Sci; 2023 Feb; 67(1):103-107. PubMed ID: 32550606
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
    Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
    J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.